| Pimavanserin | Acadia Pharma | ||
| 34 mg; Capsule, Oral |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
Less Than 5
|
Less Than 5
|
||
|
Less Than 5
|
None | ||
| Nuplazid is indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis | |||
|
Yes
| |||
| Nuplazid | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 | Patent 16 | Patent 17 | Patent 18 | Patent 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ********* | *** ********* | *** ********* | *** ********* | ********* ** **** *** | ********* ** **** *** | ******* | *** ********* | ******* | *** ********* | ******* | ******* | *** ********* | ******* | *** ********* | ******* | ******* | *** ** ** | *** ** ** | **** ** *** **, **** (***** ******) |
| **** | *** ********* | *** ********* | **** *** | **** ** **** **, **** | **** ** *** **, **** | ******* | *** ********* | ******* | *** ********* | **** *** | **** *** | *** ********* | **** *** | **** *** | **** *** | ******* | *** ** ** | *** ** ** | *** ********* (***** ******) |
| ***** ****** | *** ********* | *** ********* | *** ********* | ******* | ******* | ******* | *** ********* | ******* | *** ********* | **** *** | **** *** | *** ********* | **** *** | **** *** | **** *** | *** ** ** | *** ** ** | *** ** ** | ******* (***** ******) |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ********* | *** \ ********* | *** **, **** | *******/ ********* *** ** ** | ********* ******** | ***** *** **** (******** ******) |
| **** | *** \ *** | *** **, **** | *******/ ********* *** ** ** | ********* ******** | ***** *** **** (******** ******) |
| ***** ****** | *** \ *** | *** **, **** | ******* ***** ******* *** | ******** | ***** *** **** (******** ******) |
| Pimavanserin | Acadia Pharma | ||
| 10 mg Tablet; Oral |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
Less Than 5
|
Less Than 5
|
||
| None | None | ||
| Nuplazid is indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis | |||
|
Yes
| |||
| Nuplazid | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 | Patent 16 | Patent 17 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ***** ****** | *** ********* | *** ********* | *** ********* | ******* | *** ********* | ******* | *** ********* | ******* | *** ********* | **** *** | **** *** | *** ********* | **** *** | **** *** | **** *** | ******* | *** ********* (***** ******) |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ***** ****** | *** \ *** | *** **, **** | ******* | ********* ******** | ******* *** **** *** *** **** |
Download ParaIV Report